Baxter International (NYSE: BAX) and Lombard Medical (OTCMKTS:EVARF) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Baxter International and Lombard Medical, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Baxter International 0 5 8 1 2.71
Lombard Medical 0 0 0 0 N/A

Baxter International currently has a consensus price target of $68.92, suggesting a potential upside of 0.74%. Given Baxter International’s higher probable upside, equities research analysts clearly believe Baxter International is more favorable than Lombard Medical.


Baxter International pays an annual dividend of $0.64 per share and has a dividend yield of 0.9%. Lombard Medical does not pay a dividend. Baxter International pays out 34.6% of its earnings in the form of a dividend.


This table compares Baxter International and Lombard Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Baxter International 9.88% 15.00% 8.12%
Lombard Medical N/A N/A N/A

Earnings and Valuation

This table compares Baxter International and Lombard Medical’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Baxter International $10.16 billion 3.67 $4.97 billion $1.85 36.98
Lombard Medical $12.17 million 0.26 -$31.03 million ($1.54) -0.07

Baxter International has higher revenue and earnings than Lombard Medical. Lombard Medical is trading at a lower price-to-earnings ratio than Baxter International, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

83.8% of Baxter International shares are owned by institutional investors. Comparatively, 39.9% of Lombard Medical shares are owned by institutional investors. 0.1% of Baxter International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Baxter International has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, Lombard Medical has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500.


Baxter International beats Lombard Medical on 14 of the 16 factors compared between the two stocks.

About Baxter International

Baxter International Inc., through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapy (CRRT) and additional dialysis services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices and by patients at home under physician supervision.

About Lombard Medical

Lombard Medical, Inc. is a medical technology company. The Company specializes in developing, manufacturing, and marketing endovascular stent-grafts that address medical needs in the repair of aortic aneurysms. The Company’s Aorfix is an abdominal aortic aneurysm (AAA) stent-graft for the treatment of AAAs with angulation at the neck of the aneurysm of over 90 degrees. The Company supplies Aorfix pre-loaded into a delivery system, Aorflex, which is designed for accurate placement of Aorfix in the abdominal aorta. Once Aorfix is properly placed within the abdominal aorta, it provides a conduit for blood flow, thereby relieving pressure within the weakened or aneurysmal section of the vessel wall, which reduces the potential for the AAA to rupture. It also offers IntelliFlex, which is a delivery system technology created for Aorfix AAA stent graft, and Altura Endovascular Stent Graft System that offers a simple and predictable solution to the treatment of standard AAA anatomies.

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with Analyst Ratings Network's FREE daily email newsletter.